We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+0.11%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$709M
AUM Growth
+$195M
Cap. Flow
+$27.5M
Cap. Flow %
3.88%
Top 10 Hldgs %
69.09%
Holding
206
New
48
Increased
50
Reduced
50
Closed
43

Top Buys

Rank Stock Value
1
ATER icon
Aterian
ATER
+$8.44M
2
COCP icon
Cocrystal Pharma
COCP
+$7.74M
3
RCON icon
Recon Technology
RCON
+$7.51M
4
LNAI
Lunai Bioworks
LNAI
+$5.46M
5
KRBP
Kiromic BioPharma, Inc. Common Stock
KRBP
+$4.18M

Top Sells

Rank Stock Value
1
VANI icon
Vivani Medical
VANI
+$4.81M
2
PENN icon
PENN Entertainment
PENN
+$4.24M
3
VTSI icon
VirTra
VTSI
+$3.45M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$3.42M
5
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$2.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.19%
2 Healthcare 12.07%
3 Consumer Discretionary 1.47%
4 Financials 1.38%
5 Technology 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HMCOW
126
DELISTED
HumanCo Acquisition Corp. Warrant
HMCOW
$238K 0.03%
200,314
+59,178
+42% +$70.1K
UK icon
127
Ucommune International Ltd Class A Ordinary Shares
UK
$1.34M
$223K 0.03%
42
-12
-22% -$66.8K
HEPA
128
CALL
DELISTED
Hepion Pharmaceuticals
HEPA
$220K 0.03%
+1
New +$1.83K
PALI icon
129
Palisade Bio
PALI
$349M
$214K 0.03%
+70
New +$318K
CSCI
130
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$214K 0.03%
2,442
-3,542
-59% -$337K
PLUR icon
131
PUT
Pluri
PLUR
$14.1M
$210K 0.03%
66
-151
-70% -$5K
NMAD
132
Nomad Power Solutions
NMAD
$60.5M
$199K 0.03%
6,551
-1,423
-18% -$40.9K
HEPA
133
PUT
DELISTED
Hepion Pharmaceuticals
HEPA
$194K 0.03%
1
– –
NOVN
134
DELISTED
Novan, Inc. Common Stock
NOVN
$192K 0.03%
+19,132
New +$225K
CTRM icon
135
PUT
Castor Maritime
CTRM
$22.1M
$189K 0.03%
+73
New +$2.97K
HCDIW
136
DELISTED
Harbor Custom Development, Inc. Warrant
HCDIW
$171K 0.02%
+272,103
New +$191K
NBRV
137
PUT
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$165K 0.02%
49
+30
+158% +$1.12K
TVTX icon
138
Travere Therapeutics
TVTX
$5.86B
$147K 0.02%
+10,042
New +$198K
MMAT
139
PUT
DELISTED
Meta Materials Inc. Common Stock
MMAT
$136K 0.02%
+2
New +$1.12K
PHIO icon
140
Phio Pharmaceuticals
PHIO
$11.8M
$117K 0.02%
479
+266
+125% +$65.6K
RDHL
141
CALL
Redhill Biopharma
RDHL
$3.5M
– –
0
– –
NTBL
142
PUT
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$117K 0.02%
14
-10
-42% -$758
TRIL
143
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$117K 0.02%
121
-525
-81% -$4.94K
CRDF icon
144
PUT
Cardiff Oncology
CRDF
$110M
$111K 0.02%
167
-2
-1% -$17
POL
145
DELISTED
Polished.com Inc.
POL
$110K 0.02%
+572
New +$156K
LIXTW
146
DELISTED
Lixte Biotechnology Warrants
LIXTW
$107K 0.02%
140,089
-17,285
-11% -$12.3K
EVFM
147
PUT
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$107K 0.02%
+63
New +$1.19K
IO
148
CALL
DELISTED
ION Geophysical Corporation
IO
$105K 0.01%
+500
New +$1.07K
NMTR
149
CALL
DELISTED
9 Meters Biopharma
NMTR
$95K 0.01%
+43
New +$1.06K
CSCI
150
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$81K 0.01%
9
-11
-55% -$1.05K
4 5
6
7 8

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sabby Management held 206 positions worth $709M, up 38% from $514M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management deployed $27.5M of net new capital in Q2 2021, opening 48 new positions and adding to 50 existing holdings. Its largest new stake was Aterian: 36,083 shares worth $6.33M.

By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, up from 76% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Vivani Medical, an estimated $4.81M trimmed.

  • Sabby Management's largest Q2 2021 buy was Aterian: 36,083 shares worth $6.33M.
  • Sabby Management added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $2.87M increase.
  • Sabby Management's biggest Q2 2021 reduction was Vivani Medical, cutting an estimated $4.81M.
  • Sabby Management fully exited PENN Entertainment in Q2 2021, selling an estimated $4.24M.
  • Sabby Management's ten largest holdings make up 69% of its $709M portfolio in Q2 2021.
  • Sabby Management opened 48 new positions and closed 43 in Q2 2021.
  • Sabby Management's portfolio value rose 38% quarter-over-quarter to $709M.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.